{'fraction_non_alphanumeric': 0.0355434039644566, 'fraction_numerical': 0.00888585099111415, 'mean_word_length': 5.229787234042553, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
In Silico Design of a Novel Multi-Epitope Peptide Vaccine Against Hepatocellular Carcinoma



Hepatocellular Carcinoma (HCC) is a prevalent cancer in the world. As
yet, there is no medication for complete treatment of HCC.



There is a critical need to search for an innovative therapy for HCC. Recently, multiepitope
vaccines have been introduced as effective immunotherapy approach against HCC.



In this research, several immunoinformatics methods were applied to create an original
multi-epitope vaccine against HCC consisting of CD8+ cytolytic T lymphocytes (CTLs) epitopes
selected from α- fetoprotein (AFP), glypican-3 (GPC3), aspartyl-β-hydroxylase (ASPH); CD4+
helper T lymphocytes (HTLs) epitopes from tetanus toxin fragment C (TTFC), and finally, two tandem
repeats of HSP70407-426 were used which stimulated strong innate and adaptive immune responses.
All the mentioned parts were connected together by relevant linkers.



According to physicochemical, structural, and immunological results, the designed
vaccine is stable, non-allergen, antigen; it also has a high-quality 3D structure, and numerous linear
and conformational B cell epitopes, whereby this vaccine may stimulate efficient humoral immunity.



Center on the collected results, the designed vaccine potentially can induce cellular and
humoral immune responses in HCC cases; nonetheless, the efficiency of vaccine must be approved
within in vitro and in vivo immunological analyzes.
